Literature DB >> 21266514

Statins as anti-inflammatory therapy in HIV disease?

Andrew Carr.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21266514      PMCID： PMC3071129          DOI： 10.1093/infdis/jiq120

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  21 in total

1.  Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.

Authors:  M A Albert; E Danielson; N Rifai; P M Ridker
Journal:  JAMA       Date:  2001-07-04       Impact factor: 56.272

2.  Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.

Authors:  P M Ridker; N Rifai; M Clearfield; J R Downs; S E Weis; J S Miles; A M Gotto
Journal:  N Engl J Med       Date:  2001-06-28       Impact factor: 91.245

3.  Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection.

Authors:  Janis V Giorgi; Robert H Lyles; Jose L Matud; Traci E Yamashita; John W Mellors; Lance E Hultin; Beth D Jamieson; Joseph B Margolick; Charles R Rinaldo; John P Phair; Roger Detels
Journal:  J Acquir Immune Defic Syndr       Date:  2002-04-01       Impact factor: 3.731

4.  Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression.

Authors:  Z Liu; W G Cumberland; L E Hultin; H E Prince; R Detels; J V Giorgi
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1997-10-01

5.  Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells.

Authors:  Flore Mulhaupt; Christian M Matter; Brenda R Kwak; Graziano Pelli; Niels R Veillard; Fabienne Burger; Pierre Graber; Thomas F Lüscher; François Mach
Journal:  Cardiovasc Res       Date:  2003-09-01       Impact factor: 10.787

6.  High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial.

Authors:  Anuradha Ganesan; Nancy Crum-Cianflone; Jeanette Higgins; Jing Qin; Catherine Rehm; Julia Metcalf; Carolyn Brandt; Jean Vita; Catherine F Decker; Peter Sklar; Mary Bavaro; Sybil Tasker; Dean Follmann; Frank Maldarelli
Journal:  J Infect Dis       Date:  2011-02-15       Impact factor: 5.226

7.  Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage.

Authors:  J V Giorgi; L E Hultin; J A McKeating; T D Johnson; B Owens; L P Jacobson; R Shih; J Lewis; D J Wiley; J P Phair; S M Wolinsky; R Detels
Journal:  J Infect Dis       Date:  1999-04       Impact factor: 5.226

8.  Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1.

Authors:  Jean-François Giguère; Michel J Tremblay
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

9.  Statin-induced immunomodulatory effects on human T cells in vivo.

Authors:  Thomas Fehr; Christian Kahlert; Walter Fierz; Helen I Joller-Jemelka; Walter F Riesen; Hans Rickli; Rudolf P Wüthrich; Peter Ammann
Journal:  Atherosclerosis       Date:  2004-07       Impact factor: 5.162

10.  Lovastatin inhibits HIV-1 expression in H9 human T lymphocytes cultured in cholesterol-poor medium.

Authors:  J C Mazière; J C Landureau; P Giral; M Auclair; L Fall; A Lachgar; A Achour; D Zagury
Journal:  Biomed Pharmacother       Date:  1994       Impact factor: 6.529
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.